Drug news
NICE rejects Herceptin (Roche) as first line treatment for Post Menopausal Breast Cancer
NICE finds that the overall survival benefit of Herceptin (trastuzumab)from Roche/Genentech, alongside aromatase inhibitors as first line treatment for post menopausal breast cancer patients whose disease has spread is of small effect and uncertain and not cost effective.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.